{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:08:41Z","timestamp":1778749721252,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the construction of an individualized medication model for epilepsy in children based on artificial intelligence technology","award":["20232035"],"award-info":[{"award-number":["20232035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02094-3","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:52:48Z","timestamp":1774432368000},"page":"992-1003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized prediction of initial valproic acid dose in children with epilepsy using machine learning techniques"],"prefix":"10.1007","volume":"48","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuechun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2094_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/JNN.0000000000000199","volume":"48","author":"LV Duffy","year":"2016","unstructured":"Duffy LV, Vessey JA. A randomized controlled trial testing the efficacy of the creating opportunities for parent empowerment program for parents of children with epilepsy and other chronic neurological conditions. J Neurosci Nurs. 2016;48:166\u201374. https:\/\/doi.org\/10.1097\/JNN.0000000000000199.","journal-title":"J Neurosci Nurs"},{"key":"2094_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1474-4422(07)70127-8","volume":"6","author":"TL Mac","year":"2007","unstructured":"Mac TL, Tran DS, Quet F, et al. Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review. Lancet Neurol. 2007;6:533\u201343. https:\/\/doi.org\/10.1016\/S1474-4422(07)70127-8.","journal-title":"Lancet Neurol"},{"key":"2094_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1212\/wnl.52.4.889-a","volume":"52","author":"FK Alehan","year":"1999","unstructured":"Alehan FK, Morton LD, Pellock JM. Treatment of absence status with intravenous valproate. Neurology. 1999;52:889\u201390. https:\/\/doi.org\/10.1212\/wnl.52.4.889-a.","journal-title":"Neurology"},{"key":"2094_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","volume":"54","author":"J Ding","year":"2015","unstructured":"Ding J, Wang Y, Lin W, et al. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet. 2015;54:305\u201317. https:\/\/doi.org\/10.1007\/s40262-014-0212-8.","journal-title":"Clin Pharmacokinet"},{"key":"2094_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.pediatrneurol.2012.02.019","volume":"46","author":"KL Kwong","year":"2012","unstructured":"Kwong KL, Tsui KW, Wu SP, et al. Utilization of antiepileptic drugs in Hong Kong children. Pediatr Neurol. 2012;46:281\u20136. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2012.02.019.","journal-title":"Pediatr Neurol"},{"key":"2094_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.seizure.2012.04.014","volume":"21","author":"JM Nicholas","year":"2012","unstructured":"Nicholas JM, Ridsdale L, Richardson MP, et al. Trends in antiepileptic drug utilisation in UK primary care 1993-2008: cohort study using the General Practice Research Database. Seizure. 2012;21:466\u201370. https:\/\/doi.org\/10.1016\/j.seizure.2012.04.014.","journal-title":"Seizure"},{"key":"2094_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40:526\u201348. https:\/\/doi.org\/10.1097\/FTD.0000000000000546.","journal-title":"Ther Drug Monit"},{"key":"2094_CR8","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.927830","volume":"21","author":"JP Johnston","year":"2020","unstructured":"Johnston JP, Nerenberg SF. Valproic acid-induced thrombocytopenia-related spontaneous systemic bleeding. Am J Case Rep. 2020;21:e927830. https:\/\/doi.org\/10.12659\/AJCR.927830.","journal-title":"Am J Case Rep"},{"key":"2094_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/01.WNF.0000228209.69524.E8","volume":"29","author":"J Fleming","year":"2006","unstructured":"Fleming J, Chetty M. Therapeutic monitoring of valproate in psychiatry: how far have we progressed? Clin Neuropharmacol. 2006;29:350\u201360. https:\/\/doi.org\/10.1097\/01.WNF.0000228209.69524.E8.","journal-title":"Clin Neuropharmacol"},{"key":"2094_CR10","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.934275","volume":"27","author":"X Lan","year":"2021","unstructured":"Lan X, Mo K, Nong L, et al. Factors influencing sodium valproate serum concentrations in patients with epilepsy based on logistic regression analysis. Med Sci Monit. 2021;27:e934275. https:\/\/doi.org\/10.12659\/MSM.934275.","journal-title":"Med Sci Monit"},{"key":"2094_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.17712\/nsj.2021.4.20210075","volume":"26","author":"OY Muthaffar","year":"2021","unstructured":"Muthaffar OY, Almahmudi SM, Alrabghi MO, et al. Valproic acid for children below 2 years of age with epilepsy. Neurosciences (Riyadh). 2021;26:357\u201365. https:\/\/doi.org\/10.17712\/nsj.2021.4.20210075.","journal-title":"Neurosciences (Riyadh)"},{"key":"2094_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/FTD.0b013e3181c13a30","volume":"32","author":"J Haymond","year":"2010","unstructured":"Haymond J, Ensom MH. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder? Ther Drug Monit. 2010;32:19\u201329. https:\/\/doi.org\/10.1097\/FTD.0b013e3181c13a30.","journal-title":"Ther Drug Monit"},{"key":"2094_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106939","volume":"104","author":"A Verrotti","year":"2020","unstructured":"Verrotti A, Lattanzi S, Brigo F et al. Pharmacodynamic interactions of antiepileptic drugs: from bench to clinical practice. Epilepsy Behav. 2020;104:106939. https:\/\/doi.org\/10.1016\/j.yebeh.2020.106939.","journal-title":"Epilepsy Behav"},{"key":"2094_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cell.2020.03.022","volume":"181","author":"J Goecks","year":"2020","unstructured":"Goecks J, Jalili V, Heiser LM et al. How machine learning will transform biomedicine. Cell. 2020;181:92\u2013101. https:\/\/doi.org\/10.1016\/j.cell.2020.03.022.","journal-title":"Cell"},{"key":"2094_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/17512433.2021.1911642","volume":"14","author":"X Huang","year":"2021","unstructured":"Huang X, Yu Z, Wei X, et al. Prediction of vancomycin dose on high-dimensional data using machine learning techniques. Expert Rev Clin Pharmacol. 2021;14:761\u201371. https:\/\/doi.org\/10.1080\/17512433.2021.1911642.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2094_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104242","volume":"131","author":"Y Liu","year":"2021","unstructured":"Liu Y, Chen J, You Y, et al. An ensemble learning based framework to estimate warfarin maintenance dose with cross-over variables exploration on incomplete data set. Comput Biol Med. 2021;131:104242. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104242.","journal-title":"Comput Biol Med"},{"key":"2094_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.890221","volume":"13","author":"P Zheng","year":"2022","unstructured":"Zheng P, Yu Z, Mo L, et al. An individualized medication model of sodium valproate for patients with bipolar disorder based on machine learning and deep learning techniques. Front Pharmacol. 2022;13:890221. https:\/\/doi.org\/10.3389\/fphar.2022.890221.","journal-title":"Front Pharmacol"},{"key":"2094_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1521932","volume":"15","author":"YW Chen","year":"2024","unstructured":"Chen YW, Lin XK, Chen S, et al. Monitoring of the trough concentration of valproic acid in pediatric epilepsy patients: a machine learning-based ensemble model. Front Pharmacol. 2024;15:1521932. https:\/\/doi.org\/10.3389\/fphar.2024.1521932.","journal-title":"Front Pharmacol"},{"key":"2094_CR19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00228-025-03874-y","volume":"81","author":"J Chen","year":"2025","unstructured":"Chen J, Wang J, Li K, et al. Dosing prediction of valproic acid in pediatric patients with epilepsy: population pharmacokinetic model or machine learning model? Eur J Clin Pharmacol. 2025;81:1333\u201341. https:\/\/doi.org\/10.1007\/s00228-025-03874-y.","journal-title":"Eur J Clin Pharmacol"},{"key":"2094_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109647","volume":"151","author":"SP Li","year":"2024","unstructured":"Li SP, Lin LC, Yang RC, et al. Predicting the therapeutic response to valproic acid in childhood absence epilepsy through electroencephalogram analysis using machine learning. Epilepsy Behav. 2024;151:109647. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109647.","journal-title":"Epilepsy Behav"},{"key":"2094_CR21","unstructured":"Lundberg SM, Lee S-I (2017) A unified approach to interpreting model predictions. In: Paper presented at the Proceedings of the 31st International Conference on Neural Information Processing Systems, Long Beach, California, USA,"},{"key":"2094_CR22","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00228-003-0699-7","volume":"59","author":"ES El Desoky","year":"2004","unstructured":"El Desoky ES, Fuseau E, El Din Army S et al. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. Eur J Clin Pharmacol. 2004;59:783\u201390. https:\/\/doi.org\/10.1007\/s00228-003-0699-7","journal-title":"Eur J Clin Pharmacol"},{"key":"2094_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1358\/mf.2007.29.10.1116313","volume":"29","author":"SM Jankovic","year":"2007","unstructured":"Jankovic SM, Milovanovic JR. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. Methods Find Exp Clin Pharmacol. 2007;29:673\u20139. https:\/\/doi.org\/10.1358\/mf.2007.29.10.1116313.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"2094_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061153","author":"ES Meseguer","year":"2021","unstructured":"Meseguer ES, Elizalde MU, Borobia AM et al. Valproic acid-induced liver injury: a case-control study from a prospective pharmacovigilance program in a tertiary hospital. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10061153.","journal-title":"J Clin Med"},{"key":"2094_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/s0887-8994(02)00505-2","volume":"28","author":"EC Wirrell","year":"2003","unstructured":"Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol. 2003;28:126\u20139. https:\/\/doi.org\/10.1016\/s0887-8994(02)00505-2.","journal-title":"Pediatr Neurol"},{"key":"2094_CR26","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.1528-1167.2006.00953.x","volume":"48","author":"L de Vries","year":"2007","unstructured":"de Vries L, Karasik A, Landau Z, et al. Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia. 2007;48:470\u20137. https:\/\/doi.org\/10.1111\/j.1528-1167.2006.00953.x.","journal-title":"Epilepsia"},{"key":"2094_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1345\/aph.1L414","volume":"43","author":"S Grosso","year":"2009","unstructured":"Grosso S, Mostardini R, Piccini B et al. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann Pharmacother. 2009;43:45\u201350. https:\/\/doi.org\/10.1345\/aph.1L414.","journal-title":"Ann Pharmacother"},{"key":"2094_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1177\/1091581809340329","volume":"28","author":"MS Lee","year":"2009","unstructured":"Lee MS, Jung BH, Chung BC, et al. Metabolomics study with gas chromatography-mass spectrometry for predicting valproic acid-induced hepatotoxicity and discovery of novel biomarkers in rat urine. Int J Toxicol. 2009;28:392\u2013404. https:\/\/doi.org\/10.1177\/1091581809340329.","journal-title":"Int J Toxicol"},{"key":"2094_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/clpt.2011.47","volume":"89","author":"KE Price","year":"2011","unstructured":"Price KE, Pearce RE, Garg UC, et al. Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study. Clin Pharmacol Ther. 2011;89:867\u201374. https:\/\/doi.org\/10.1038\/clpt.2011.47.","journal-title":"Clin Pharmacol Ther"},{"key":"2094_CR30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s40262-022-01171-w","volume":"61","author":"K Lin","year":"2022","unstructured":"Lin K, Cao VFS, Au C, Dahri K. Clinical pharmacokinetic monitoring of free valproic acid levels: a systematic review. Clin Pharmacokinet. 2022;61:1345\u201363. https:\/\/doi.org\/10.1007\/s40262-022-01171-w.","journal-title":"Clin Pharmacokinet"},{"key":"2094_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1742-7843.2006.pto_402.x","volume":"98","author":"GA Karikas","year":"2006","unstructured":"Karikas GA, Schulpis KH, Bartzeliotou A, et al. Lipids, lipoproteins, apolipoproteins, selected trace elements and minerals in the serum of children on valproic acid monotherapy. Basic Clin Pharmacol Toxicol. 2006;98:599\u2013603. https:\/\/doi.org\/10.1111\/j.1742-7843.2006.pto_402.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2094_CR32","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1016\/j.febslet.2008.08.028","volume":"582","author":"CC Aires","year":"2008","unstructured":"Aires CC, Soveral G, Luis PB, et al. Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes. FEBS Lett. 2008;582:3359\u201366. https:\/\/doi.org\/10.1016\/j.febslet.2008.08.028.","journal-title":"FEBS Lett"},{"key":"2094_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1023\/a:1005398516208","volume":"20","author":"MF Silva","year":"1997","unstructured":"Silva MF, Ruiter JP, Illst L, et al. Valproate inhibits the mitochondrial pyruvate-driven oxidative phosphorylation in vitro. J Inherit Metab Dis. 1997;20:397\u2013400. https:\/\/doi.org\/10.1023\/a:1005398516208.","journal-title":"J Inherit Metab Dis"},{"key":"2094_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1528-1167.2009.02206.x","volume":"51","author":"A Verrotti","year":"2010","unstructured":"Verrotti A, Manco R, Agostinelli S, et al. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia. 2010;51:268\u201373. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02206.x.","journal-title":"Epilepsia"},{"key":"2094_CR35","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1177\/088307389901400802","volume":"14","author":"GP Novak","year":"1999","unstructured":"Novak GP, Maytal J, Alshansky A, et al. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol. 1999;14:490\u20135. https:\/\/doi.org\/10.1177\/088307389901400802.","journal-title":"J Child Neurol"},{"key":"2094_CR36","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/17512433.2018.1501556","volume":"11","author":"SA Hamed","year":"2018","unstructured":"Hamed SA, Rageh TA, Mohamad AO et al. Renal dysfunctions\/injury in adult epilepsy patients treated with carbamazepine or valproate. Expert Rev Clin Pharmacol. 2018;11:819\u201324. https:\/\/doi.org\/10.1080\/17512433.2018.1501556.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2094_CR37","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.tiv.2010.03.014","volume":"24","author":"Q Ji","year":"2010","unstructured":"Ji Q, Shi X, Lin R, et al. Participation of lipid transport and fatty acid metabolism in valproate sodium-induced hepatotoxicity in HepG2 cells. Toxicol In Vitro. 2010;24:1086\u201391. https:\/\/doi.org\/10.1016\/j.tiv.2010.03.014.","journal-title":"Toxicol In Vitro"},{"key":"2094_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00819","volume":"10","author":"S Xu","year":"2019","unstructured":"Xu S, Chen Y, Ma Y, et al. Lipidomic profiling reveals disruption of lipid metabolism in valproic acid-induced hepatotoxicity. Front Pharmacol. 2019;10:819. https:\/\/doi.org\/10.3389\/fphar.2019.00819.","journal-title":"Front Pharmacol"},{"key":"2094_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1034\/j.1399-5618.2002.01162.x","volume":"4","author":"JP Hennion","year":"2002","unstructured":"Hennion JP, el-Masri MA, Huff MO et al. Evaluation of neuroprotection by lithium and valproic acid against ouabain-induced cell damage. Bipolar Disord. 2002;4:201\u20136. https:\/\/doi.org\/10.1034\/j.1399-5618.2002.01162.x.","journal-title":"Bipolar Disord"},{"key":"2094_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040811","author":"P Teixeira-da-Silva","year":"2022","unstructured":"Teixeira-da-Silva P, Perez-Blanco JS, Santos-Buelga D, et al. Population pharmacokinetics of valproic acid in pediatric and adult Caucasian patients. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14040811.","journal-title":"Pharmaceutics"},{"key":"2094_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1228641","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Liu M, Qin W, et al. Modeling the protein binding non-linearity in population pharmacokinetic model of valproic acid in children with epilepsy: a systematic evaluation study. Front Pharmacol. 2023;14:1228641. https:\/\/doi.org\/10.3389\/fphar.2023.1228641.","journal-title":"Front Pharmacol"},{"key":"2094_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.994665","volume":"13","author":"X Zhu","year":"2022","unstructured":"Zhu X, Zhang M, Wen Y et al. Machine learning advances the integration of covariates in population pharmacokinetic models: valproic acid as an example. Front Pharmacol. 2022;13:994665. https:\/\/doi.org\/10.3389\/fphar.2022.994665.","journal-title":"Front Pharmacol"},{"key":"2094_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jad.2023.11.047","volume":"347","author":"CW Hsu","year":"2024","unstructured":"Hsu CW, Lai EC, Chen YB et al. Valproic acid monitoring: serum prediction using a machine learning framework from multicenter real-world data. J Affect Disord. 2024;347:85\u201391. https:\/\/doi.org\/10.1016\/j.jad.2023.11.047.","journal-title":"J Affect Disord"},{"key":"2094_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/9996553","volume":"2023","author":"Y Yao","year":"2023","unstructured":"Yao Y, Zhao J, Wang Y, et al. Development and internal validation of machine learning algorithms for determining sodium valproate concentrations below the standard level using a risk prediction model of children with epilepsy. J Clin Pharm Ther. 2023;2023:9996553. https:\/\/doi.org\/10.1155\/2023\/9996553.","journal-title":"J Clin Pharm Ther"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02094-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:16:04Z","timestamp":1778746564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02094-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2094"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02094-3","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships, which may be considered potential competing interests: methodological guidance and data analysis were provided by Beijing Medicinovo Technology Co., Ltd. and Dalian Medicinovo Technology\u00a0Co., Ltd.The authors declare the following financial interests\/personal relationships, which may be considered potential competing interests: methodological guidance and data analysis were provided by Beijing Medicinovo Technology Co., Ltd. and Dalian Medicinovo Technology\u00a0Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Helsinki Declaration of 1964 and approved by the ethics committee of Baoding Hospital, Beijing Children\u2019s Hospital, affiliated with the Capital Medical University (No.2025\u201364).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent for participation was not provided by the participant\u2019s legal guardians\/next of kin, because study data have been fully de-identified, and confidential information of patients has been deleted, in accordance with the CIOMS\/WHO International Ethical Guidelines for Health-related Research Involving Humans (2016), and the study was deemed exempt from informed consent by study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publish"}},{"value":"informed consent from the patients\u2019 legal guardians was not required because all data were de-identified and anonymized in line with the CIOMS\/WHO International Ethical Guidelines for Health-related Research Involving Humans (2016).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}